MedTrace Logo

A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants

NCT05668936 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2023-04-05

No results posted yet for this study

Summary

This study will investigate the effect of multiple doses of cotadutide on the cardiac activity (QTc interval) of healthy participants.

Conditions

  • Non-alcoholic Steatohepatitis

Interventions

DRUG

Cotadutide

Participants will receive a subcutaneous injection of cotadutide.

DRUG

Cotadutide-placebo

Participants will receive a subcutaneous injection of cotadutide-placebo.

DRUG

Moxifloxacin

Participants will receive a single oral dose of Moxifloxacin film-coated tablet.

DRUG

Moxifloxacin-placebo

Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-03
Primary Completion
2023-03-10
Completion
2023-03-10

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05668936 on ClinicalTrials.gov